Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model

Annals of Thoracic Surgery

Volumn 71, Issue 5, 2001, Pages 1657-1665

  Boehle, Arnd S ^a   Sipos, Bence ^a   Kliche, Ursula ^a   Kalthoff, Holger ^a   Dohrmann, Peter ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN A4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; METASTASIS; MOUSE; PRIORITY JOURNAL; TUMOR GROWTH; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PRODRUGS; STILBENES; TUMOR CELLS, CULTURED;

EID: 0035019116     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(01)02408-0     Document Type: Article

References (25)

1. Mountain C.F. The international system for staging lung cancer. Semin Surg Oncol. 18:2000;106-115.
2. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 333:1995;1757-1763.
3. Dhanabal M., Ramchandran R., Waterman M.J.F., et al. Endostatin induces endothelial cell apoptosis. J Biol Chem. 274:1999;11721-11726.
4. Pettit G.R., Singh S.B., Hamel E., Lin C.M., Alberts D.S., Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 45:1989;209-211.
5. Woods J.A., Hadfield J.A., Pettit G.R., Fox B.W., McGown A.T. The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer. 71:1995;705-711.
6. Pettit G.R., Temple C., Narayanan V.L., et al. Antineoplastic agents 322. Synthesis of combretastatin A4-prodrugs. Anticancer Drug Design. 10:1995;299-309.
7. Dark G.G., Hill S.A., Prise V.E., Tozer G.M., Pettit G.R., Chaplin D.J. Combretastatin A-4, an agent that displays potent and selective toxicity towards tumor vasculature. Cancer Res. 57:1997;1829-1834.
8. Beauregard D.A., Thelwall P.E., Chaplin D.J., Hill S.A., Adams G.E., Brindle K.M. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumor perfusion and energetic status. Br J Cancer. 77:1998;1761-1767.
9. Tozer G.M., Prise V.E., Wilson J., et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent early effects in tumors and normal tissues . Cancer Res. 59:1999;1626-1634.
10. Zhao S., Moore J.V., Waller M.L., et al. Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4. Eur J Nucl Med. 26:1999;231-238.
11. Li L., Rojiani A., Siemann D.W. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate effects on radiation therapy . Int J Radiat Oncol Biol Phys. 42:1998;899-903.
12. Horsman M.R., Ehrnrooth E., Ladekarl M., Overgaard J. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys. 42:1998;895-898.
13. Ohsumi K., Nakagawa R., Fukuda Y., et al. Novel combretastatin analogues effective against murine solid tumors design and structure-activity relationships . J Med Chem. 41:1998;3022-3032.
14. Boehle A.S., Dohrmann P., Leuschner I., Kalthoff H., Henne-Bruns D. An improved orthotopic xenotransplant procedure of human lung cancer in SCID bg mice. Ann Thor Surg. 69:2000;1010-1015.
15. Weidner M., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 324:1991;1-8.
16. Mattern J., Koomagi R., Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer. 73:1996;931-934.
17. Lin C.M., Singh S.B., Chu P.S., et al. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin a structure activity study . Mol Pharmacol. 34:1988;200-208.
18. Iyer S., Chaplin D.J., Rosenthal D.S., Boulares A.H., Li L.Y., Smulson M. Induction of apoptosis in proliferating endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res. 58:1998;4510-4514.
19. Bohle A.S., Leuschner I., Kalthoff H., Henne-Bruns D. Combretastatin A4 Prodrug - a potent inhibitor of malignant hemangioendothelioma cell proliferation. Int J Cancer. 87:2000;838-843.
20. Zhang S.X., Bastow K.F., Tachibana Y., et al. Antitumor agents. 196. Substituted 2-thienyl-1, 8-naphthyridin-4-ones their synthesis, cytotoxicity, and inhibition of tubulin polymerization(1) . J Med Chem. 42:1999;4081-4087.
21. El-Zayat A.A., Degen D., Drabek S., Clark G.M., Pettit G.R., Von Hoff D.D. In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from combretum caffrum (arid shrub). Anticancer Drugs. 4:1993;19-25.
22. Chaplin D.J., Pettit G.R., Hill S.A. Anti-vascular approaches to solid tumor therapy evaluation of combretastatin A4 phosphate . Anticancer Res. 19:1999;189-195.
23. Dorr R.T., Dvorakova K., Snead K., Albert D.S., Salmon S.E., Pettit G.R. Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Invest New Drugs. 14:1996;131-137.
24. Gallo R.L., Dorschner R.A., Takashima S., Klagsbrun M., Eriksson E., Bernfield M. Endothelial cell surface alkaline phosphatase activity is induced by IL-6 released during wound repair. J Invest Dermatol. 109:1997;597-603.
25. Brogi E., Schatteman G., Wu T., et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. Clin Invest. 97:1996;469-476.